Physician profile
Shiny Michael
NPI 1669986667
$892.49
in general payments reported to CMS, 2019-2025
14 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.71 · 2022: $12.27 · 2023: $366 · 2024: $355 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $793.52 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $162.51 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $134.83 | 2022-2025 | |
| Amgen INC. | $97.35 | 2021-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $85.97 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $77.25 | 2023-2024 | |
| Glaxosmithkline, LLC. | $75.56 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $70.97 | 2023 | Spravato |
| Novo Nordisk INC | $43.63 | 2023 | Wegovy |
| Dynavax Technologies Corporation | $43.50 | 2023-2024 | Heplisav-B |
| Inari Medical, INC. | $25.32 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Dexcom, INC. | $24.96 | 2025 | Dexcom G6 Transmitter |
| Seqirus USA INC | $18.63 | 2024 | Flucelvax, Fluad |
| Lilly USA, LLC | $17.85 | 2023 | Mounjaro |
| Inspire Medical Systems, INC. | $14.16 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiny Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.